EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions

Carol R Bradford iD, Sreeram M P iD, Karthik N Rao iD, Orlando Guntinas-Lichius iD, Nabil Saba iD, Alfio Ferlito

Head & Neck · 2026-09 · 48 (9) · 2584-2592

DOI: 10.1002/hed.70385 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Head & Neck, online erschienen am 09.07.2026. Verfasst von Carol R Bradford und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Immunotherapy, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Head and neck squamous cell carcinoma (HNSCC) is frequently diagnosed at advanced stages and has historically been associated with poor outcomes. Immune checkpoint inhibition has transformed the therapeutic landscape, offering durable responses in recurrent, metastatic, and locally advanced disease.

Methods

This review summarizes pivotal clinical trials evaluating immunotherapeutic strategies in HNSCC, including PD‐1/PD‐L1 inhibitors, combination regimens, and emerging modalities across recurrent/metastatic and curative‐intent settings, with attention to efficacy, safety, and biomarkers.

Results

Phase III trials have established pembrolizumab and nivolumab as standards of care in recurrent or metastatic HNSCC, demonstrating improved overall survival and favorable toxicity profiles. Recent studies support earlier integration of immunotherapy, including neoadjuvant and adjuvant approaches, with meaningful gains in event‐free and disease‐free survival.

Conclusions

Immunotherapy is reshaping the management of HNSCC. Ongoing trials, biomarker refinement, and novel strategies are expected to further expand benefit and personalize treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckImmune Checkpoint InhibitorsHumansAntibodies, Monoclonal, HumanizedNivolumab

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorspembrolizumabNivolumab

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
  • Sri Shankara Cancer Hospital and Research Centre, Bangalore, India.
  • Head and Neck Surgical Oncology Department, Sri Shankara Cancer Hospital and Research Centre, Bangalore, India.
  • ENT Department, Jena University Hospital, Jena, Germany.
  • Department of Hematology and Medical Oncology, The Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  • International Head and Neck Scientific Group, Padua, Italy.

ORCID-Profile: Carol R Bradford, Sreeram M P, Karthik N Rao, Orlando Guntinas-Lichius, Nabil Saba

Zitieren

APA

Bradford, C. R., M P, S., Rao, K. N., Guntinas-Lichius, O., Saba, N., & Ferlito, A. (2026). Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions. Head & Neck, 48(9), 2584-2592. https://doi.org/10.1002/hed.70385

Vancouver

Bradford CR, M P S, Rao KN, Guntinas-Lichius O, Saba N, Ferlito A. Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions. Head & Neck. 2026;48(9):2584-2592. doi:10.1002/hed.70385

BibTeX
@article{Bradford2026,
  author = {Bradford, Carol R and M P, Sreeram and Rao, Karthik N and Guntinas-Lichius, Orlando and Saba, Nabil and Ferlito, Alfio},
  title = {Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions},
  journal = {Head & Neck},
  year = {2026},
  volume = {48},
  number = {9},
  pages = {2584--2592},
  doi = {10.1002/hed.70385}
}
Kostenlos starten →